A randomized controlled trial of an Internet-based intervention for eating disorders and the added value of expert-patient support: study protocol.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
16 Aug 2019
Historique:
received: 31 10 2018
accepted: 12 07 2019
entrez: 18 8 2019
pubmed: 20 8 2019
medline: 11 2 2020
Statut: epublish

Résumé

E-mental health has become increasingly popular in interventions for individuals with eating disorders (EDs). It has the potential to offer low-threshold interventions and guide individuals to the needed care more promptly. Featback is such an Internet-based intervention and consists of psychoeducation and a fully automated monitoring and feedback system. Preliminary findings suggest Featback to be (cost-)effective in reducing ED symptomatology. Additionally, e-mail or chat support by a psychologist did not enhance the effectiveness of Featback. Support by an expert patient (someone with a lived experience of an ED) might be more effective, since that person can effectively model healthy behavior and enhance self-efficacy in individuals struggling with an ED. The present study aims to replicate and build on earlier findings by further investigating the (cost-)effectiveness of Featback and the added value of expert-patient support. The study will be a randomized controlled trial with a two-by-two factorial design with repeated measures. The four conditions will be (1) Featback, in which participants receive automated feedback on a short monitoring questionnaire weekly, (2) Featback with weekly e-mail or chat support from an expert patient, (3) weekly support from an expert patient, and (4) a waiting list. Participants who are 16 years or older and have at least mild self-reported ED symptoms receive a baseline measure. Subsequently, they are randomized to one of the four conditions for 8 weeks. Participants will be assessed again post-intervention and at 3, 6, 9, and 12 months follow-up. The primary outcome measure will be ED psychopathology. Secondary outcome measures are experienced social support, self-efficacy, symptoms of anxiety and depression, user satisfaction, intervention usage, and help-seeking attitudes and behaviors. The current study is the first to investigate e-mental health in combination with expert-patient support for EDs and will add to the optimization of the delivery of Internet-based interventions and expert-patient support. Netherlands Trial Register, NTR7065 . Registered on 7 June 2018.

Sections du résumé

BACKGROUND BACKGROUND
E-mental health has become increasingly popular in interventions for individuals with eating disorders (EDs). It has the potential to offer low-threshold interventions and guide individuals to the needed care more promptly. Featback is such an Internet-based intervention and consists of psychoeducation and a fully automated monitoring and feedback system. Preliminary findings suggest Featback to be (cost-)effective in reducing ED symptomatology. Additionally, e-mail or chat support by a psychologist did not enhance the effectiveness of Featback. Support by an expert patient (someone with a lived experience of an ED) might be more effective, since that person can effectively model healthy behavior and enhance self-efficacy in individuals struggling with an ED. The present study aims to replicate and build on earlier findings by further investigating the (cost-)effectiveness of Featback and the added value of expert-patient support.
METHODS METHODS
The study will be a randomized controlled trial with a two-by-two factorial design with repeated measures. The four conditions will be (1) Featback, in which participants receive automated feedback on a short monitoring questionnaire weekly, (2) Featback with weekly e-mail or chat support from an expert patient, (3) weekly support from an expert patient, and (4) a waiting list. Participants who are 16 years or older and have at least mild self-reported ED symptoms receive a baseline measure. Subsequently, they are randomized to one of the four conditions for 8 weeks. Participants will be assessed again post-intervention and at 3, 6, 9, and 12 months follow-up. The primary outcome measure will be ED psychopathology. Secondary outcome measures are experienced social support, self-efficacy, symptoms of anxiety and depression, user satisfaction, intervention usage, and help-seeking attitudes and behaviors.
DISCUSSION CONCLUSIONS
The current study is the first to investigate e-mental health in combination with expert-patient support for EDs and will add to the optimization of the delivery of Internet-based interventions and expert-patient support.
TRIAL REGISTRATION BACKGROUND
Netherlands Trial Register, NTR7065 . Registered on 7 June 2018.

Identifiants

pubmed: 31420063
doi: 10.1186/s13063-019-3574-2
pii: 10.1186/s13063-019-3574-2
pmc: PMC6697984
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

509

Subventions

Organisme : ZonMw
ID : 636310001

Références

Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
J Health Econ. 1995 Jun;14(2):171-89
pubmed: 10154656
Psychol Methods. 2002 Jun;7(2):147-77
pubmed: 12090408
Int J Nurs Stud. 2003 Mar;40(3):321-32
pubmed: 12605954
J Abnorm Soc Psychol. 1961 May;62:713-5
pubmed: 13875334
Int J Eat Disord. 2004 Nov;36(3):280-95
pubmed: 15478137
Br J Gen Pract. 2005 Nov;55(520):831-7
pubmed: 16281998
Int J Eat Disord. 2006 Dec;39(8):667-76
pubmed: 16868992
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005108
pubmed: 17943839
Int J Eat Disord. 2008 May;41(4):368-71
pubmed: 18306345
J Epidemiol Community Health. 2008 Apr;62(4):361-7
pubmed: 18339831
Med J Aust. 2008 Nov 17;189(10 Suppl):S21-4
pubmed: 19143586
Health Expect. 2009 Dec;12(4):396-406
pubmed: 19691464
Int J Eat Disord. 2010 Nov 1;43(7):633-47
pubmed: 19806607
Psychosomatics. 2009 Nov-Dec;50(6):613-21
pubmed: 19996233
Eval Health Prof. 2010 Mar;33(1):56-80
pubmed: 20164106
Int J Eat Disord. 2010 Apr;43(3):195-204
pubmed: 20186717
Int J Behav Nutr Phys Act. 2010 May 11;7:36
pubmed: 20459779
Gen Hosp Psychiatry. 2011 Jan-Feb;33(1):29-36
pubmed: 21353125
Eat Weight Disord. 2010 Dec;15(4):e234-9
pubmed: 21406946
Clin Psychol Rev. 2011 Jul;31(5):727-35
pubmed: 21501580
Qual Life Res. 2012 Feb;21(1):167-76
pubmed: 21598064
Clin Pract Epidemiol Ment Health. 2011;7:74-83
pubmed: 21687562
Am J Orthopsychiatry. 2011 Jul;81(3):351-9
pubmed: 21729015
Int J Eat Disord. 2012 Apr;45(3):428-38
pubmed: 21744375
Eur Eat Disord Rev. 2012 Jan;20(1):1-8
pubmed: 21796737
Psychol Assess. 2012 Sep;24(3):565-72
pubmed: 22082035
Health Psychol. 2014 Jan;33(1):52-65
pubmed: 22924446
Hum Nat. 2013 Sep;24(3):336-47
pubmed: 23881574
Curr Opin Psychiatry. 2013 Nov;26(6):543-8
pubmed: 24060914
Trials. 2013 Oct 17;14:340
pubmed: 24135131
Health Econ. 2015 Mar;24(3):258-69
pubmed: 24254584
PLoS One. 2013 Dec 19;8(12):e85287
pubmed: 24367708
BMC Psychiatry. 2014 Feb 14;14:39
pubmed: 24528545
J Eat Disord. 2014 Aug 22;2(1):24
pubmed: 25426293
Behav Res Ther. 2014 Dec;63:122-31
pubmed: 25461787
Am J Community Psychol. 2015 Jun;55(3-4):455-71
pubmed: 25861883
Trials. 2015 Apr 16;16:165
pubmed: 25885697
Int J Eat Disord. 2015 Sep;48(6):775-8
pubmed: 26052695
PLoS One. 2015 Jun 08;10(6):e0129688
pubmed: 26053921
Int J Eat Disord. 2016 Jan;49(1):19-31
pubmed: 26607683
Value Health. 2015 Dec;18(8):994-9
pubmed: 26686783
Eat Behav. 2016 Apr;21:66-75
pubmed: 26761787
J Ment Health. 2016 Oct;25(5):441-447
pubmed: 26850624
Curr Psychiatry Rep. 2016 Apr;18(4):42
pubmed: 26946513
J Med Internet Res. 2016 Jun 17;18(6):e159
pubmed: 27317358
Value Health. 2016 Jun;19(4):343-52
pubmed: 27325326
Int J Eat Disord. 2016 Dec;49(12):1068-1076
pubmed: 27441418
BMC Public Health. 2016 Aug 24;16(1):864
pubmed: 27558630
Pharmacoeconomics. 2016 Nov;34(11):1071-1074
pubmed: 27613159
Behav Res Ther. 2017 Feb;89:66-74
pubmed: 27907817
BMC Psychiatry. 2017 Feb 2;17(1):46
pubmed: 28148234
Eur Psychiatry. 2017 May;42:103-110
pubmed: 28364685
Cochrane Database Syst Rev. 2017 Apr 19;4:CD012331
pubmed: 28421600
J Consult Clin Psychol. 2017 Sep;85(9):883-895
pubmed: 28425735
Pain. 2017 Aug;158(8):1437-1445
pubmed: 28644822
Behav Res Methods. 2018 Oct;50(5):2016-2034
pubmed: 29071652
Int J Eat Disord. 2017 Dec;50(12):1378-1384
pubmed: 29076172
PLoS One. 2017 Nov 9;12(11):e0187477
pubmed: 29121647
BMC Res Notes. 2017 Dec 07;10(1):709
pubmed: 29212554
Pilot Feasibility Stud. 2018 Apr 18;4:75
pubmed: 29750119
Eat Disord. 2018 Nov-Dec;26(6):556-574
pubmed: 30222057
Int J Eat Disord. 1994 Nov;16(3):227-38
pubmed: 7833956
Int J Eat Disord. 1994 Dec;16(4):363-70
pubmed: 7866415
Tijdschr Gerontol Geriatr. 1994 Oct;25(5):192-6
pubmed: 7974641
Int J Eat Disord. 1993 May;13(4):369-84
pubmed: 8490639

Auteurs

Pieter J Rohrbach (PJ)

GGZ Rivierduinen Eetstoornissen Ursula, Postbox 405, Sandifortdreef 19, 2300 AK, Leiden, the Netherlands. p.rohrbach@rivierduinen.nl.

Alexandra E Dingemans (AE)

GGZ Rivierduinen Eetstoornissen Ursula, Postbox 405, Sandifortdreef 19, 2300 AK, Leiden, the Netherlands.
Institute of Psychology, Leiden University, Leiden, the Netherlands.

Philip Spinhoven (P)

Institute of Psychology, Leiden University, Leiden, the Netherlands.
Department of Psychiatry, Leiden University Medical Center, Leiden, the Netherlands.

Elske Van den Akker-Van Marle (E)

Department of Biomedical Data Sciences, Section Medical Decision Making, Leiden University Medical Center, Leiden, the Netherlands.

Joost R Van Ginkel (JR)

Institute of Psychology, Leiden University, Leiden, the Netherlands.

Marjolein Fokkema (M)

Institute of Psychology, Leiden University, Leiden, the Netherlands.

Markus Moessner (M)

Center for Psychotherapy Research, University of Heidelberg, Heidelberg, Germany.

Stephanie Bauer (S)

Center for Psychotherapy Research, University of Heidelberg, Heidelberg, Germany.

Eric F Van Furth (EF)

GGZ Rivierduinen Eetstoornissen Ursula, Postbox 405, Sandifortdreef 19, 2300 AK, Leiden, the Netherlands.
Department of Psychiatry, Leiden University Medical Center, Leiden, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH